Summit Research Peptides
FDA issued a warning letter to Summit Research Peptides (Hoover, AL) on December 10, 2024, after reviewing the company's website and Facebook page and finding that products marketed as Semaglutide, Retatrutide, Cagrilintide, Tirzepatide, and Mazdutide were being sold as unapproved new drugs for human use despite 'Research Use Only' labeling. The agency found that product descriptions and social media posts established intended human therapeutic use — including claims about weight loss, glucose control, and cardiovascular health — in violation of FD&C Act sections 505(a) and 301(d). No FDA-approved applications are in effect for these products. FDA demanded a written response within 15 working days and warned that failure to comply may result in seizure or injunction.
Flagged claims (13)
Optimized Cardiovascular Health: Support your heart health with this powerful combination. Promote better cardiovascular health and ensure your heart remains strong and healthy.
Mazdutide is an investigational peptide with a novel dual-action mechanism, designed to mimic and enhance the biological activities of certain endogenous hormones. It is at the forefront of research in metabolic disorders and has shown promising results in early studies related to weight management and glucose regulation.
Achieve Your Weight Loss Goals Faster with Cagrilintide & Semaglutide
Sema is a GLP-1 analog with therapeutic applications in type 2 diabetes and obesity. It enhances insulin secretion and reduces appetite, leading to improved glycemic control and weight loss.
Tirzepatide is a cutting-edge synthetic derivative of the Glucagon-Like Peptide-1 (GLP-1), designed specifically for the scientific community to advance research in metabolic disorders and diabetes management.
Exhibits cardioprotective and neuroprotective potential
Reta is an experimental tritagonist drug targeting three hormone receptors: GLP-1, GIP, and glucagon. It is designed to mimic these hormones' effects, such as enhancing satiety, regulating blood sugar, and suppressing appetite.
Supports weight management in obesity
GLP-1 analog simulating human incretin activity
Reta presents a promising approach for obesity and diabetes treatment, offering a novel mechanism of action through a triple-receptor agonist profile. It's a significant development in the search for more effective treatments for these conditions.
Improved Glucose Management: Maintain stable blood sugar levels and achieve effective glucose control with the combined benefits of Cagrilintide and Semaglutide, enhancing your overall metabolic health
Enhances insulin secretion and beta cell function
Unlock Maximum Health Benefits with Cagrilintide and Semaglutide . . . designed to help you achieve your health goals more effectively than ever before! Enhanced Weight Loss: Achieve superior weight reduction with the synergistic effects of Cagrilintide and Semaglutide. Experience greater weight loss results and take control of your journey to a healthier you.
Required actions (2)
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.
Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most glp-1 / weight loss sites match 3-6 patterns.
Run my free site auditWorried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker